Table 1. Baseline Characteristics of Patients and Control Participants.
| Variable | Primary cohort | Stratification | ||||
|---|---|---|---|---|---|---|
| Inflammatory demyelinating CNS events | Inflammatory nondemyelinating CNS events | |||||
| Control participants | Patients | Control participants | Patients | Control participants | Patients | |
| Patients, No. | 106 | 106 | 56 | 56 | 50 | 50 |
| Women, No. (%) | 68 (64) | 68 (64) | 40 (71) | 40 (71) | 28 (56) | 28 (56) |
| Age at autoimmune disease diagnosis, median (IQR), y | 35 (23-46) | 36 (25-48) | 34 (20-41) | 34 (24-43) | 36 (26-53) | 42 (26-59) |
| Autoimmune disease, No. (%) | ||||||
| Rheumatoid arthritis | 48 (45) | 48 (45) | 26 (46) | 26 (46) | 22 (44) | 22 (44) |
| Ankylosing spondylitis | 4 (4) | 4 (4) | 1 (2) | 1 (2) | 3 (6) | 3 (6) |
| Psoriasis and psoriatic arthritis | 21 (20) | 21 (20) | 12 (21) | 12 (21) | 9 (18) | 9 (18) |
| Crohn disease | 27 (25) | 27 (25) | 14 (25) | 14 (25) | 13 (26) | 13 (26) |
| Ulcerative colitis | 6 (6) | 6 (6) | 3 (5) | 3 (5) | 3 (6) | 3 (6) |
| Disease duration at index date, median (IQR), y | 13 (6-22) | 12 (5-19) | 13 (6-19) | 12 (6-19) | 15 (8-25) | 8 (4-17) |
Abbreviations: CNS, central nervous system; IQR, interquartile range.